Bavarian Nordic Enters Additional Monkeypox Vaccine Supply Contract with the European Health Emergency Preparedness and Response Authority (HERA)
- New contract will double the supply of monkeypox vaccines to HERA before year-end
- Company upgrades financial guidance for 2022
COPENHAGEN, Denmark, September 7, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the European Health Emergency Preparedness and Response Authority (HERA) has ordered an additional 170,000 doses of MVA-BN smallpox/monkeypox vaccine, which will be made available to EU Member States, Norway and Iceland.
With deliveries scheduled before year-end, the new order will double the supply of monkeypox vaccines to HERA in 2022.
Paul Chaplin, President and CEO of Bavarian Nordic said: “European countries remain significantly affected by monkeypox and many EU Member States depend on the availability of vaccines through HERA to be able to respond to the outbreak. We are pleased to supply additional vaccines for deployment already this year, enabling HERA to step up their efforts in the short term.”
As a consequence of the recent order inflow, and considering the uncertainty associated with exact timing of supply of products close to year end, Bavarian Nordic raises its expectations for the financial results for 2022 with revenue now expected to be between DKK 2,800 and 3,000 million (previously between DKK 2,700 and 2,900 million) and EBITDA raised to a result between DKK 0 and a loss of DKK 200 million (previously a loss between DKK 100 and 300 million). The year-end cash position is expected to exceed DKK 1,700 million.
The European Health Emergency Preparedness and Response Authority (HERA) was established by the European Commission in September 2021 with the purpose to strengthen Europe’s ability to prevent, detect, and rapidly respond to cross-border health emergencies, by ensuring the development, manufacturing, procurement, and equitable distribution of key medical countermeasures.
About the smallpox/monkeypox vaccine
MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic (marketed as IMVANEX® in Europe, JYNNEOS® in the U.S. and IMVAMUNE® in Canada) is a non-replicating smallpox vaccine developed in collaboration with the U.S. government to ensure supply of a smallpox vaccine for the entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines. The vaccine was approved by the European Commission in 2013 for immunization against smallpox in adults aged 18 years and older and has subsequently gained regulatory approvals in Canada and the U.S. where the approval has been extended to include the monkeypox indication as the only vaccine having obtained this to-date.
Bavarian Nordic has ongoing supply contracts with USA and Canada and has delivered the vaccine to a number of undisclosed countries globally as part of their national biological preparedness. In recent years, smaller quantities of the vaccine have been supplied in response to sporadic cases of monkeypox. During the ongoing 2022 outbreak of monkeypox, Bavarian Nordic has worked with several governments and organizations to fulfil the immediate demand for the vaccine through a number of supply agreements and is working to secure manufacturing of vaccines to fulfil the demand in the medium- to long term.
About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. The vaccine is also approved in Europe and Canada. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine. For more information visit www.bavarian-nordic.com.
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, firstname.lastname@example.org, Tel: +1 781 686 9600
Company Announcement no. 34 / 2022
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Iveco Group: periodic report on the buyback program4.12.2023 17:50:00 CET | Press release
Turin, 4th December 2023. Iveco Group N.V. (EXM: IVG) announces that, under the ongoing initial tranche of the common share buyback program announced on 14th April 2023, the Company completed on a daily basis, starting from 27th November 2023 to 1st December 2023 the following transactions: DateNumber of repurchased Common SharesAverage net price (euro)Total net consideration (euro)27 November 202337,8007.2557274,266.1228 November 202338,3007.3074279,872.2029 November 202337,3007.4251276,956.9630 November 202336,9007.4309274,201.681 December 202336,6007.5204275,245.06Total186,9007.38651,380,542.03 An overall overview of the purchases carried out under the current share buyback program as well as the details of the above transactions, are available on the Company’s corporate website at the following address: https://www.ivecogroup.com/investors/stock_information/share_buyback. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to adv
AB Linas Agro Group: notification on disposal of voting rights4.12.2023 17:34:50 CET | Press release
AB Linas Agro Group, ISIN code LT0000128092 (hereinafter - the Company), received notification from UAB “INVL Asset Management” on the disposal of voting rights (enclosed). Additional information: Mažvydas Šileika, Finance Director of AB Linas Agro Group Mob. +370 619 19 403 E-mail email@example.com Attachment Notification on disposal of block of shares_UAB INVL Asset Management
Innofactor Plc: Share Repurchase 4.12.20234.12.2023 17:30:00 CET | Press release
Innofactor Plc Announcement 4.12.2023Innofactor Plc: Share Repurchase 4.12.2023In the Helsinki Stock ExchangeTrade date 4.12.2023Bourse trade BuyShare IFA1VAmount 4,700SharesAverage price/ share 1.1600EURTotal cost 5,452.00EURInnofactor Plc now holds a total of 566 529 sharesincluding the shares repurchased on 4.12.2023On behalf of Innofactor PlcNordea Bank OyjJanne Sarvikivi Sami HuttunenAdditional information:Sami Ensio, CEOInnofactor PlcTel. +358 50 584 firstname.lastname@example.org Attachment Innofactor_4.12_trades
Borregaard ASA: Share buy-back programme completed4.12.2023 16:58:26 CET | Press release
04.12.2023: Borregaard ASA (”Borregaard”, OSE ticker: BRG) Reference is made to the stock exchange notice of 17 November 2023 where Borregaard announced the intent to repurchase up to 200,000 of its outstanding common stock. The repurchase of shares will be conducted in a period from 20th November up to and including 20th December 2023 at the latest. Borregaard has in the period from 29 November up to and including 4 December in total purchased 60,204 own shares through broker at an average price of NOK 173.24 per share. By these transactions, Borregaard has completed its share buy-back programme by repurchasing 200,000 shares of its outstanding common stock. Aggregated overview of transactions per day: DateAggregated daily volume (number of shares)Weighted average share price per day (NOK)Total daily transaction value (NOK)29.11.20239,142173.32161,584,506.0730.11.202317,258172.80752,982,311.8401.12.202316,902172.73082,919,495.9804.12.202316,902174.14862,943,459.64Previously disclosed
BBS-Bioactive Bone Substitutes Plc: Managers' Transactions - Pekka Jalovaara4.12.2023 15:45:00 CET | Press release
BBS-Bioactive Bone Substitutes Plc, Company announcement, Management transactions, 4 December 2023 at 4.45 p.m. (EET) BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Pekka Jalovaara ____________________________________________ Person subject to the notification requirement Name: Jalovaara Pekka Position: Member of the Board/Deputy member Issuer: BBS Bioactive Bone Substitutes Oyj LEI: 743700BYSBP0PCR6N767 Notification type: INITIAL NOTIFICATION Reference number: 743700BYSBP0PCR6N767_20231203205051_6 ____________________________________________ Transaction date: 2023-11-30 Venue not applicable Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT ISIN: FI4000260583 Nature of the transaction: DISPOSAL Transaction details (1): Volume: 126,606 Unit price: 0.005012 EUR Aggregated transactions (1): Volume: 126,606 Volume weighted average price: 0.005012 EUR ____________________________________________ Person subject to the notification requirement Name: J